In February, ChromoTek welcomed its 20,000th customer.

ChromoTek launched Nano-CaptureLigands for specific and site-directed capture of antibodies for SPR, BLI, and ELISA assays. Also V5-Trap for unparalleled immunoprecipitation of V5-tagged proteins was released. In October, ChromoTek became part of the Proteintech Group.

ChromoTek launches Nano-Secondaries^®: monoclonal recombinant Nanobodies to bind with high specificity and affinity to rabbit and mouse primary antibodies in a subtype specific manner.

ChromoTek launches the Spot-capture and detection system for universal applications: This is the first peptide-tag and Nanobody used in super resolution microscopy. The inert Spot-Tag^® and Nanobody can also applied in immunoprecipitation, purification, Western blotting and immunofluorescence.

Highest number of literature references establishes GFP-Trap^® as the gold standard for immunoprecipitation of GFP-fusion proteins and their interacting partners.

• ChromoTek opens a subsidiary on East Coast to strengthens its customers’ support in the US.
• ChromoTek’s Fluorescent 2-Hybrid (F2H^®) technology enables screening and validation of compounds in living cells.

• ChromoTek licenses Chromobody^® technology for high content drug profiling to Bayer
• ChromoTek introduces Chromobody plasmids for real time monitoring of key intracellular target molecules in vivo.

ChromoTek moves into IZB in Martinsried

ChromoTek introduces Nano-Boosters and Nano-Labels: fluorescently labeled Nanobodies for advanced immunofluorescence.

• ChromoTek launches GFP-Trap, the worldwide first Nanobody-based reagent for immunoprecipitation of fluorescent proteins
• ChromoTek starts to pioneer the use of Nanobodies for research applications
• Foundation of ChromoTek GmbH in Munich, Germany